CD226

CD226
Structures disponibles
PDB	Recherche d'orthologue: PDBe RCSB
Identifiants PDB
	6ISA, 6ISC, 6ISB, 6O3O
Identifiants
Aliases	CD226
IDs externes	OMIM: 605397 MGI: 3039602 HomoloGene: 4787 GeneCards: CD226
Position du gène (Homme)
Chr.	Chromosome 18 humain
Fin	69,961,803 bp
Position du gène (Souris)
Chr.	Chromosome 18 (souris)
Fin	89,290,353 bp
Expression génétique
	Fortement exprimé dans
	monocyte; ; granulocyte; ; sang; ; ganglion lymphatique; ; gonade; ; testicule; ; rate; ; appendice iléo-cæcal; ; nerf sural; ; epithelium of colon;
	Fortement exprimé dans
	sang; ; zygote; ; rate; ; thymus; ; ganglion mésentérique; ; embryon; ; moelle osseuse; ; secondary oocyte; ; subcutaneous adipose tissue; ; œsophage;
	Plus de données d'expression de référence
	Plus de données d'expression de référence
Gene Ontology
Fonction moléculaire	protein homodimerization activity; liaison protéique; protein kinase binding; integrin binding; cell adhesion molecule binding;
Composant cellulaire	integral component of plasma membrane; radeau lipidique; integral component of membrane; membrane; surface cellulaire; external side of plasma membrane; membrane plasmique;
Processus biologique	positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target; adhésion cellulaire; regulation of immune response; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; homophilic cell adhesion via plasma membrane adhesion molecules; positive regulation of Fc receptor mediated stimulatory signaling pathway; cell recognition; cytokine production; positive regulation of immunoglobulin mediated immune response; transduction de signal; positive regulation of natural killer cell mediated cytotoxicity; positive regulation of mast cell activation; positive regulation of interferon-gamma production; positive regulation of natural killer cell cytokine production; positive regulation of T cell receptor signaling pathway;
	Sources:Amigo / QuickGO
Orthologues
	10666
	225825
	ENSG00000150637
	ENSMUSG00000034028
	Q15762
	Q8K4F0
	NM_001303618; NM_001303619; NM_006566
	NM_001039148; NM_001039149; NM_178687
	NP_001290547; NP_001290548; NP_006557
	NP_001034238; NP_848802
	Wikidata
Voir/Editer Humain	Voir/Editer Souris

Le CD226 (ou DNAM-1) est une protéine de type cluster de différenciation dont le gène, CD226, est situé sur le chromosome 18 humain. Il agit comme un récepteur à la surface de certains lymphocytes

Rôles

Ses ligands sont le CD155^[5] et le CD112^[6]. Il permet la stimulation des lymphocytes NK, avec production de cytokines dans certains cancers^[5]. Son action sur le CD155 est cependant contrecarrée par le CD96^[7].

Le CD226 facilite également la différenciation et la prolifération des lymphocytes par son interaction avec le LFA-1^[8].

En médecine

Plusieurs médicaments utilisés dans le traitement du myélome multiple, tel que la doxorubicine, le melphalan, ou le bortezomib, stimulent ce récepteur, et par ce biais, les lymphocytes NK^[9].

Notes et références

↑ ^{a b et c} GRCh38: Ensembl release 89: ENSG00000150637 - Ensembl, May 2017
↑ ^{a b et c} GRCm38: Ensembl release 89: ENSMUSG00000034028 - Ensembl, May 2017
↑ « Publications PubMed pour l'Homme », sur National Center for Biotechnology Information, U.S. National Library of Medicine
↑ « Publications PubMed pour la Souris », sur National Center for Biotechnology Information, U.S. National Library of Medicine
↑ ^{a et b} Chan CJ, Andrews DM, McLaughlin NM et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases, J Immunol, 2010;184:902–911
↑ de Andrade LF, Smyth MJ, Martinet L, DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins, Immunol Cell Biol, 2014;92:237–244
↑ Chan CJ, Martinet L, Gilfillan S et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions, Nat Immunol, 2014;15:431–438
↑ Shibuya K, Shirakawa J, Kameyama T et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation, J Exp Med, 2003;198:1829–1839
↑ Soriani A, Zingoni A, Cerboni C et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype, Blood, 2009;113:3503–3511

[refGRCh38Ensembl-1] {a b et c} GRCh38: Ensembl release 89: ENSG00000150637 - Ensembl, May 2017

[refGRCm38Ensembl-2] {a b et c} GRCm38: Ensembl release 89: ENSMUSG00000034028 - Ensembl, May 2017

[3] « Publications PubMed pour l'Homme », sur National Center for Biotechnology Information, U.S. National Library of Medicine

[4] « Publications PubMed pour la Souris », sur National Center for Biotechnology Information, U.S. National Library of Medicine

[Chan_2010-5] {a et b} Chan CJ, Andrews DM, McLaughlin NM et al. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases, J Immunol, 2010;184:902–911

[de_Andrade_2014-6] Andrade LF, Smyth MJ, Martinet L, DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins, Immunol Cell Biol, 2014;92:237–244

[Chan_2014-7] Chan CJ, Martinet L, Gilfillan S et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions, Nat Immunol, 2014;15:431–438

[Shibuya_2003-8] Shibuya K, Shirakawa J, Kameyama T et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation, J Exp Med, 2003;198:1829–1839

[Soriani_2009-9] Soriani A, Zingoni A, Cerboni C et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype, Blood, 2009;113:3503–3511

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]